DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS PRIOR APPROVAL PROFORMA REQUIRED SPECIALIST CENTRE ONLY (includng outreach when delivered as part of a provider network) SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE) ABACAVIR HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ ABACAVIR + LAMIVUDINE + DOLUTEGRAVIR (TRIUMEQ®) HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND CLINICAL COMMISSIONING POLICY: B06/P/b/AGREED REGIONAL GUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ ABACAVIR + LAMIVUDINE HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ ABALOPARATIDE MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND DRUGS AFFECTING BONE METABOLISM NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ABATACEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373 NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ ABIRATERONE CANCER NHS ENGLAND HORMONE ANTAGONISTS TA259, 387 (SEE ALSO SSC1438) ONLY IN ENZALUTAMIDE NAÏVE PATIENTS NICE/NHS ENGLAND POLICY NICE SACT √ √ ADALIMUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373 NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ ADALIMUMAB UVEITIS - ADULTS NHS ENGLAND CYTOKINE MODULATORS TA460 NICE NICE NICE AUDIT √ √ ADALIMUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √ ADALIMUMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS NICE TA 392 NICE NICE NICE AUDIT √ √ ADEFOVIR HEPATITIS B NHS ENGLAND VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS NOT ROUTINELY COMMISSIONED (CG165) AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ AFATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA310 NICE NICE SACT √ AFLIBERCEPT CANCER NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED (TA307) AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ AGALSIDASE ALFA FABRY'S DISEASE NHS ENGLAND DRUGS USED IN METABOLIC DISORDERS NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED DATABASE √ AGALSIDASE BETA FABRY'S DISEASE NHS ENGLAND DRUGS USED IN METABOLIC DISORDERS NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED DATABASE √ ALBUTROPIN ADULT ONSET GROWTH HORMONE DEFICIENCY NHS ENGLAND GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ALDESLEUKIN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ ALEMTUZUMAB MULTIPLE SCLEROSIS NHS ENGLAND DRUGS AFFECTING THE IMMUNE RESPONSE TA312 AND NHS ENGLAND POLICY STATEMENT 170075P NICE NICE NICE AUDIT √ √**** ALEMTUZUMAB PRE-TRANSPLANT IMMUNOSUPPRESSION NHS ENGLAND DRUGS AFFECTING THE IMMUNE RESPONSE TRUST GUIDELINES: ISLET TRANSPLANTATION (ONLY IF PROVIDED AT ZERO DRUG COST) TRUST GUIDELINES TRUST GUIDELINES √ ALEMTUZUMAB CLL NHS ENGLAND DRUGS AFFECTING THE IMMUNE RESPONSE TRUST GUIDELINES: (ONLY IF PROVIDED AT ZERO DRUG COST) TRUST GUIDELINES TRUST GUIDELINES SACT √ ALEMTUZUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY (ONLY IF PROVIDED AT ZERO DRUG COST) HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √ ALGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND DRUGS USED IN METABOLIC DISORDERS NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED DATABASE √ ALIPOGENE TIPARVOVEC LIPOPROTEIN LIPASE DEFICIENCY NHS ENGLAND DRUGS USED IN METABOLIC DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ALISPORIVIR HEPATITIS C NHS ENGLAND VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ALPHA MANNOSIDASE RECOMBINANT HUMAN ALPHA MANNOSIDASE DEFICIENCY NHS ENGLAND DRUGS USED IN METABOLIC DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ AMBRISENTAN PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMANORY ARTERIAL HYPERTENSION NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ AMIFAMPRIDINE PHOSPHATE LEMS NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16009/P AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ AMIKACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ AMIKACIN LIPOSOMAL CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ AMPHOTERICIN LIPOSOMAL FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY √ ANABASUM SCLERODERMA NHS ENGLAND DRUGS AFFECTING THE IMMUNE RESPONSE NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ANAKINRA JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ ANAKINRA PERIODIC FEVERS AND AUTOINFLAMMATORY CONDITIONS NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170062P NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ ANAKINRA CRYOPYRIN ASSOCIATED PERIODIC SYNDROME NHS ENGLAND CYTOKINE MODULATORS CRYOPYRIN ASSOCIATED PERIODIC SYNDROME SERVICE SPECIFICATION HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED DATABASE √ ANAKINRA ADULT ONSET STILLS DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170056P NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ ANIDULAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY √ ANIFROLUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ANTILYMPHOCYTE GLOBULIN APLASTIC ANAEMIA ORGAN TRANSPLANT NHS ENGLAND DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √ ANTIPSEUDOMONAS AERUGINOSA IgY CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ANTITHROMBIN III AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √ MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND VERSION 14 PUBLISHED APRIL 2019 NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 1 04/04/2019
12
Embed
MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES … · MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND VERSION 14 PUBLISHED APRIL 2019 NHS
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
ADALIMUMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS NICE TA 392 NICE NICE NICE AUDIT √ √
ADEFOVIR HEPATITIS B NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUS
NOT ROUTINELY COMMISSIONED
(CG165)AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AFATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA310 NICE NICE SACT √
AFLIBERCEPT CANCER NHS ENGLAND CANCER EXCLUSIONNOT ROUTINELY COMMISSIONED
(TA307)AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
AGALSIDASE ALFA FABRY'S DISEASE NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
AGALSIDASE BETA FABRY'S DISEASE NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
ALBUTROPIN ADULT ONSET GROWTH HORMONE
DEFICIENCY NHS ENGLANDGROWTH HORMONE & GROWTH
HORMONE RECEPTOR ANTAGONISTNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ALDESLEUKIN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
ALEMTUZUMAB MULTIPLE SCLEROSIS NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSE
TA312 AND NHS ENGLAND POLICY
STATEMENT 170075PNICE NICE NICE AUDIT √ √****
ALEMTUZUMABPRE-TRANSPLANT
IMMUNOSUPPRESSIONNHS ENGLAND
DRUGS AFFECTING THE IMMUNE
RESPONSE
TRUST GUIDELINES: ISLET
TRANSPLANTATION (ONLY IF PROVIDED
AT ZERO DRUG COST)
TRUST GUIDELINES TRUST GUIDELINES √
ALEMTUZUMAB CLL NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSE
TRUST GUIDELINES: (ONLY IF
PROVIDED AT ZERO DRUG COST)TRUST GUIDELINES TRUST GUIDELINES SACT √
ALEMTUZUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS
HIGHLY SPECIALISED CRITERIA ONLY
(ONLY IF PROVIDED AT ZERO DRUG
COST)
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED CRITERIA √
ALGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
ALIPOGENE TIPARVOVEC LIPOPROTEIN LIPASE DEFICIENCY NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ALISPORIVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ALPHA MANNOSIDASE
RECOMBINANT HUMANALPHA MANNOSIDASE DEFICIENCY NHS ENGLAND
DRUGS USED IN METABOLIC
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AMBRISENTANPULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A11/P/cNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
AMIFAMPRIDINE PHOSPHATE LEMS NHS ENGLAND NEUROMUSCULAR DISORDERSNOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY: 16009/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AMIKACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AMIKACIN LIPOSOMALCYSTIC FIBROSIS
NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND
VERSION 14 PUBLISHED APRIL 2019
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 1 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
ANTITHYMOCYTE
IMMUNOGLOBULIN
APLASTIC ANAEMIA
ORGAN TRANSPLANTNHS ENGLAND
DRUGS USED IN HYPOPLASTIC,
HAEMOLYTIC, AND RENAL ANAEMIASBCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
ARIMOCLOMOL NIEMANN-PICK DISEASE NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ASFOTASE ALFA HYPOPHOSPHATASIA NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSHST6 NICE NICE AS PER MAA √ √
ASUNAPREVIR + DACLATASVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ATACICEPT SLE NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSENOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AUTOLOGOUS SERUM EYE DROPS DRY EYE NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AVACOPAN ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AXITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA333 (also refer to circular SSC1508) NICE NICE SACT √
AZACITIDINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME TA218 NICE NICE SACT √
AZTREONAM LYSINE CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGSNHS ENGLAND CLINCAL
COMMISSIONING POLICY: A01/P/bNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √*
AZTREONAM LYSINECYSTIC FIBROSIS (CONTIUOUS
TREATMENT)NHS ENGLAND ANTIBACTERIAL DRUGS
NOT ROUTINELY COMMISSIONED
NHS ENGLAND CLINCAL
COMMISSIONING POLICY: 16001/P
AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BARDOXOLONE METHYLPULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BASILIXIMAB RENAL TRANSPLANT NHS ENGLANDCORTICOSTEROIDS AND OTHER
IMMUNOSUPPRESSANTSTA85 & TA99 NICE NICE √
BECLABUVIR HEPATITIS CNHS ENGLAND
VIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BEDAQUILINE EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGSNHS ENGLAND CLINICAL
COMMISSIONING POLICY: F04/P/aNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
BEDAQUILINE MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGSNHS ENGLAND CLINICAL
COMMISSIONING POLICY: F04/P/aNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
BEGELOMAB GRAFT VERSUS HOST DISEASE NHS ENGLANDMALIGNANT DISEASE AND
IMMUNOSUPPRESSIONNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BELATACEPT RENAL TRANSPLANT NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSE
NOT ROUTINELY COMMISSIONED - NICE
TA IN PROGRESSNICE TA IN PROGRESS NICE TA IN PROGRESS NICE TA IN PROGRESS √
BELIMUMAB SLE NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSENICE TA 397 NICE NICE NICE AUDIT √ √
BENRALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NICE TA 565 NICE NICE NICE AUDIT √ √
BEPERMINOGENE PERPLASMID PERIPHERAL VASCULAR DISEASE NHS ENGLAND GENE THERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BETAINE HOMOCYSTINURIA NHS ENGLANDDRUGS USED IN METABOLIC
BEVACIZUMAB NEUROFIBROMATOSIS NHS ENGLAND ANTINEOPLASTIC DRUGSAS PER NATIONAL PROTOCOL (SEE NF2
SERVICE SPEC)
AS PER NATIONAL
PROTOCOL
AS PER NATIONAL
PROTOCOLAS PER NATIONAL PROTOCOL √
BICTECRAVIRHIV IN COMBINATION WITH OTHER
ANTI-RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BIMAGRUMAB INCLUSION BODY MYOSITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BIOTIN MULTIPLE SCLEROSIS NHS ENGLAND VITAMINS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BLISIBIMODSYSTEMIC LUPUS ERYTHEMATOSUS
(SLE)NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BOCEPREVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA253 NICE NICE HEPATITIS C MDS √
BORTEZOMIBORGAN REJECTION POST KIDNEY
TRANSPLANTNHS ENGLAND ANTINEOPLASTIC DRUGS
NOT ROUTINELY COMMISSIONED
(NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A07/P/c)
AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BORTEZOMIB CANCERNHS ENGLAND/
CDFANTINEOPLASTIC DRUGS
TA129, TA228, TA311, TA 378
CDF POLICY
NOT ROUTINELY COMMISSIONED
(NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 170035P,
170074P)
NICE
CDF
NICE
CDFSACT √
BOSENTAN DIGITAL ULCERS NHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A13/P/bNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
BOSENTANPULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A11/P/cNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
BOSUTINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 401 NICE NICE SACT √ √
BOTULINUM TOXIN FOCAL SPASTICITY IN CHILDREN NHS ENGLANDTORSION DYSTONIAS AND OTHER
INVOLUNTARY MOVEMENTSAGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √
BOTULINUM TOXIN*** INTRAVESICAL USE IN SPINAL CORD
INJURYNHS ENGLAND
TORSION DYSTONIAS AND OTHER
INVOLUNTARY MOVEMENTSAGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √
BRIMAPITIDEACUTE SENSORINEURAL HEARING
LOSSNHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BRINCIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BUROSUMAB X LINKED HYPOPHOSPHATAEMIA NHS ENGLANDDRUGS AFFECTING THE IMMUNE
COMMISSIONING POLICY: B09/P/bNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
C1 ESTERASE INHIBITORSHEREDITARY ANGIOEDEMA -
PROPHYLACTIC TREATMENTNHS ENGLAND ALLERGIC EMERGENCIES
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16045/PNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
C1 ESTERASE INHIBITORS
HEREDITARY ANGIOEDEMA -
PROPHYLACTIC TREATMENT IN
CHILDREN (CINRYZE ONLY)
NHS ENGLAND ALLERGIC EMERGENCIESAS PER NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16045/PNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
CABOTEGRAVIRHIV IN COMBINATION WITH OTHER
ANTI-RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CALCIFIDIOLINBORN ERRORS IN PRIMARY BILE
ACID SYNTHESISNHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 2 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
CANAKINUMABCRYOPYRIN ASSOCIATED PERIODIC
SYNDROMENHS ENGLAND IMMUNOMODULATING DRUGS
CRYOPYRIN ASSOCIATED PERIODIC
SYNDROME SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
CANAKINUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND IMMUNOMODULATING DRUGSNOT ROUTINELY COMMISSIONED
(TA302)AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CANNABIDIOL (AS EPIDIOLEX) DRAVET/LENNOX GESTAUT SYNDROME NHS ENGLAND CANNABINOIDS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CARGLUMIC ACID UREA CYCLE DISORDERS NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
CARNITINE CARNITINE DEFICIENCY NHS ENGLANDDRUGS USED IN METABOLIC
CENEGERMIN NEUROTROPHIC KERATITIS NHS ENGLAND ATMPNOT ROUTINELY COMMISSIONED
(TA 532)AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CERALIFIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CINACALCET HYPERPARATHYROIDISM NHS ENGLANDDRUGS FOR MINERAL BONE
DISORDERS
TA117
NHS ENGLAND POLICY 16034/P
NICE
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY√
CIPROFLOXACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CIPROFLOXACIN LIPOSOMAL
(INHALED)
CYSTIC FIBROSISNHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HISTIOCYTOSISNHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CLAZAKIZUMAB ANTIBODY MEDICATED REJECTION NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
COBICISTATHIV IN COMBINATION WITH OTHER
ANTI-RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:
F03/P/b/AGREED REGIONAL GUIDELINES
NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
CO-CARELDOPA INTESTINAL GEL PARKINSON'S DISEASE NHS ENGLAND NEURODEGENERATIVE CONDITIONSNHS ENGLAND CLINICAL
COMMISSIONING POLICY: D04/P/eNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COLISTIMETHATE SODIUM CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A01/P/b
TA276
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY
NICE AUDIT√* √*
CONESTAT ALFAHEREDITARY ANGIOEDEMA - ACUTE
TREATMENT ONLYNHS ENGLAND ALLERGIC EMERGENCIES
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: B09/P/bNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
CRIZANLIZUMAB SICKLE CELL DISEASE NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CRIZOTINIB CANCER NHS ENGLAND/CDF PROTEIN KINASE INHIBITORSNICE TA 406, 422
CDF (TA 529)
NICE
CDF
NICE
CDFSACT √ √
CYCLIC PYRANOPTERIN
MONOPHOSPHATEMOLYBDENUM COFACTOR DEFICIENCY NHS ENGLAND
DRUGS USED IN METABOLIC
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CYSTEAMINE (MERCAPTAMINE) NEPHROPATHIC CYSTINOSIS NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
DABRAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA321, TA396 & TA 544 NICE NICE SACT √ (not TA321) √
DACLATASIVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA 364 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √
DACLIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DARBOPOETIN ALPHA DIALYSIS-INDUCED ANAEMIA NHS ENGLAND
DRUGS USED IN HYPOPLASTIC,
HAEMOLYTIC, AND RENAL ANAEMIAS -
IRON OVERLOAD
RENAL DIALYSIS ONLY, INCLUDING VIA
OUTPATIENTS, AND ONLY AS PER NICE
CG114
TRUST GUIDELINES TRUST GUIDELINESPRODUCT WITH LOWEST
DEXRAZOXANE ANTHRACYCLINE CARDIOTOXICITY NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 3 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
DIBOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEINNHS ENGLAND CLINICAL
COMMISSIONING POLICY 16063/PNHS ENGLAND POLICY NHS ENGLAND POLICY AUDIT, BSR REGISTRY √
DICHLORPHENAMIDEPRIMARY HYPO AND HYPERKALAEMIC
PERIODIC PARALYSISNHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DIROXIMEL FUMARATE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DOLUTEGRAVIRHIV IN COMBINATION WITH OTHER
ANTI-RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: B06/P/a/
AGREED REGIONAL GUIDELINES
NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
DOMAGROZUMAB DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DORAVIRINEHIV iN COMBINATION WITH OTHER ANTI-
RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DORNASE ALFA PRIMARY CILIARY DYSKINESIA NHS ENGLAND MUCOLYTICSNOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY 16029/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DORNASE ALFA CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICSNHS ENGLAND CLINICAL
COMMISSIONING POLICY: A01/P/bNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √*
DRISAPERSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DUPILUMAB ASTHMA NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSENOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ECALLANTIDEHEREDITARY ANGIOEDEMA - ACUTE
TREATMENT ONLYNHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ECULIZUMABORGAN REJECTION POST KIDNEY
TRANSPLANTNHS ENGLAND
PAROXYSMAL NOCTURNAL
HAEMOGLOBINURIA
NOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY: A07/P/bAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ECULIZUMABC3 GLOMERULOPATHY (POST
TRANSPLANT)NHS ENGLAND
PAROXYSMAL NOCTURNAL
HAEMOGLOBINURIA
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16054/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ECULIZUMAB AHUS NHS ENGLANDPAROXYSMAL NOCTURNAL
HAEMOGLOBINURIA
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:
E03/PS(HSS)/A
NICE HST1
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY
NICE√ √
ECULIZUMABPAROXYSMAL NOCTURNAL
HAEMOGLOBINURIANHS ENGLAND
PAROXYSMAL NOCTURNAL
HAEMOGLOBINURIA
NHS NATIONAL SPECIALISED
COMMISSIONING TEAM SERVICE
SPECIFICATION
NSCT SERVICE SPEC NSCT SERVICE SPEC NSCT SERVICE SPEC √
EDASALONEXENT DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EDRATIDE SLE NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSENOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENZALUTAMIDE CANCER NHS ENGLAND HORMONE ANTAGONISTS
TA316, TA 377 (SEE ALSO SSC1439)
BOTH: ONLY IN ABIRATERONE NAÏVE
PATIENTS
NICE/NHS ENGLAND POLICY NICESACT √
EPOETIN ALPHA, BETA, THETA AND
ZETADIALYSIS-INDUCED ANAEMIA NHS ENGLAND
DRUGS USED IN HYPOPLASTIC,
HAEMOLYTIC, AND RENAL ANAEMIAS -
IRON OVERLOAD
RENAL DIALYSIS ONLY, INCLUDING VIA
OUTPATIENTS, AND ONLY AS PER NICE
CG114
TRUST GUIDELINES TRUST GUIDELINESPRODUCT WITH LOWEST
PROCUREMENT COST TO BE USED√
EPOPROSTENOL (5)PULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A11/P/cNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
EPRATUZUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EPRODISATE AMYLOIDOSIS NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EPTOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ERLOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORSTA162, TA227, TA 374& IN PROGRESS
NHSE LETTERNICE NICE SACT √
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 4 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
ETANERCEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: E03/P/d; TA
373
NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ETELCALCETIDEHYPERPARATHYROIDISM - DIALYSIS
PATIENTS ONLYNHS ENGLAND
DRUGS FOR MINERAL BONE
DISORDERSTA448 NICE NICE √ √
ETEPLIRSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SPECIALISED INDICATIONSNHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR VIIIAS PER BCSH GUIDELINES FOR
SPECIALISED INDICATIONSNHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES, see also SSC 1818 BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR VIII INHIBITOR
BYPASSING FACTOR (FEIBA)
AS PER BCSH GUIDELINES FOR
SPECIALISED INDICATIONSNHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR XIIIAS PER BCSH GUIDELINES FOR
SPECIALISED INDICATIONSNHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FAMPRIDINE MULTIPLE SCLEROSIS NHS ENGLAND NEUROMUSCULAR DISORDERSNOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY: 16010/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √****
GENE THERAPYSOMATOSTATIN ANALOGUE NHS ENGLAND SOMATOSTATIN ANALOGUES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FINGOLIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGSTA254
NHS ENGLAND POLICY: D04/P/bNHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
FITUSIRAN HAEMOPHILIA A AND B NHS ENGLANDANAEMIAS AND SOME OTHER BLOOD
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FORIGERIMOD ACETATE SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GANETESPIB CANCER NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSENOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
GEFITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA192 NICE NICE SACT √
GEVOKIZUMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GIVOSIRAN HEPATIC PORPHYRIA NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GLATIRAMER MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA527 & NHS ENGLAND POLICY: D04/P/b NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √****
GLECAPREVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
GLUCARPIDASEMETHOTREXATE INDUCED RENAL
DYSFUNCTIONNHS ENGLAND POISONING
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: B15/P/aNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
GLYCEROL PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GRANULOCYTE-MACROPHAGE
COLONY-STIMULATING FACTOR
(LEUKINE® - IMPORT)
ANTIBODY-POSITIVE PULMONARY
ALVEOLAR PROTEINOSISNHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GRAZOPREVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
HIV VACCINE HIV INFECTION PROPHYLAXIS NHS ENGLAND VACCINES AND ANTISERA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEM ARGINATE HEPATIC PORPHYRIA NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
HUMAN ALPHA-1 PROTEINASE
INHIBITOREMPHYSEMA NHS ENGLAND DRUGS USED FOR EMPHYSEMA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HUMAN HETEROLOGOUS LIVER
CELLSUREA CYCLE DISORDERS NHS ENGLAND
DRUGS USED IN METABOLIC
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HUMAN PARATHYROID HORMONE-
RELATED PROTEIN ANALOGUE
MALE AND JUVENILE OSTEOPOROSIS
HYPOPARATHYROIDISMNHS ENGLAND
DRUGS AFFECTING BONE
METABOLISMNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 5 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
IBALIZUMABHIV iN COMBINATION WITH OTHER ANTI-
RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ICATIBANTHEREDITARY ANGIOEDEMA - ACUTE
TREATMENT ONLYNHS ENGLAND ALLERGIC EMERGENCIES
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: B09/P/bNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
ICATIBANTHEREDUTARY ANGIOEDEMA -
PROPHYLACTIC TREATMENTNHS ENGLAND ALLERGIC EMERGENCIES
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16045/PNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
IDEBENONE DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IDURSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
ILOPROST (5)PULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A11/P/cNHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
IMATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA70, TA86, TA251, TA326 NICE NICE SACT √
IMATINIBCHRONIC GRAFT VERSUS HOST
DISEASENHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:16069/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
IMETELSTAT CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IMIGLUCERASE GAUCHER'S DISEASE NHS ENGLANDDRUGS USED IN METABOLIC
INEBILIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORSNHS ENGLAND CLINICAL
COMMISSIONING POLICY: E03/P/dNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
INFLIXIMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS
NOT ROUTINELY COMMISSIONED
(NHS ENGLAND CLINICAL
COMMISSIONING POLICY: D12/P/a &
D12/P/a)
AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMABCONNECTIVE TISSUE DISEASE -
INTERSTITAL LUNG DISEASENHS ENGLAND CYTOKINE MODULATORS
NOT ROUTINELY COMMISSIONED -
POLICY IN PROGRESSAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB CROHN'S DISEASE IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA187 NICE NICE NICE AUDIT √
INFLIXIMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB RENAL NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB PULMONARY SARCOIDOSIS NHS ENGLAND CYTOKINE MODULATORSNOT ROUTINELY COMMISSIONED
NHS ENGAND POLICY 170088PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORSNOT ROUTINELY COMMISSIONED -
NHS ENGLAND POLICY 16018/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LANADELUMAB HEREDITARY ANGIOEDEMA NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LANREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINESPRODUCT WITH LOWEST
LANREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINESPRODUCT WITH LOWEST
PROCUREMENT COST TO BE USED√ √
LANTHANUM CARBONATE ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS TRUST GUIDELINES TRUST GUIDELINES √
LAPATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
LAQUINIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √****
LARONIDASE MUCOPOLYSACCHARIDOSIS NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
LEBRIKIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LENALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA171, TA322 NICE NICE SACT √
ANTI-RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LETERMOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LEVOFLOXACIN (INHALED) CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND POLICY 170078P NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
LEVOKETOCONAZOLE CUSHING'S DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LIXIVAPTANHYPONATRAEMIA AND OTHER
ENDOCRINE USESNHS ENGLAND
POSTERIOR PITUITARY HORMONES
AND ANTAGONISTSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LOMITAPIDEHOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA NHS ENGLAND LIPID-REGULATING DRUGS NHS ENGLAND POLICY 170059P NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
LONAFARNIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LOPINAVIR + RITONAVIRHIV IN COMBINATION WITH OTHER
HORMONE RECEPTOR ANTAGONISTNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MACITENTANPULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A11/P/cAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MANNITOL CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A01/P/b
TA266
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY
NICE AUDIT√
MARALIXIBAT ALAGILLE SYNDROME NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MARAVIROC NATALIZUMAB INDUCED PML NHS ENGLAND AIDS/HIV ANTIRETROVIRALS
NOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY STATEMENT
170040P
AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MARIBAVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MASITINIB PANCREATIC CANCER/GIST NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NUSINERSEN SPINAL MUSCULAR ATROPHY NHS ENGLAND NEURODEGENERATIVE CONDITIONS
NOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY STATEMENT
170038P
AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OBETICHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSTA443 NICE NICE NICE AUDIT √ √
OCRELIZUMAB MULTIPLE SCLEROSIS NHS ENGLANDDRUGS AFFECTING THE IMMUNE
RESPONSETA 533 NICE NICE NICE AUDIT √ √****
OCTOCOG ALFA HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES: See also SSC 1818 AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OCTREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINESPRODUCT WITH LOWEST
PROCUREMENT COST TO BE USED√
OFATUMUMAB CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA344 NICE NICE SACT √
OFATUMUMAB PEMPHIGUS VULGARIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OLESOXIME SPINAL MUSCULAR ATROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AVIR + DASABUVIR + RIBAVIRINHEPATITIS C NHS ENGLAND
VIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA 365 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
OSILODROSTAT CUSHING'S DISEASE NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OZANIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PACRITINIB MYELOFIBROSIS NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
USE)INTESTINAL FAILURE NHS ENGLAND PARENTERAL NUTRITION AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM AUDIT √ √
PARENTERAL NUTRITION
(INPATIENT USE)
INTESTINAL FAILURE; INADEQUATE/
UNSAFE ENTERAL FEEDINGNHS ENGLAND PARENTERAL NUTRITION
ONLY WHEN DURATION OF PN IS > 14
DAYS OR INITIATED PRIOR TO
ADMISSION. ADULTS; SEE ALSO CG32.
SEE ALSO 'MANUAL FOR PRESCRIBED
SPECIALISED SERVICES'
TRUST GUIDELINES TRUST GUIDELINES √
PARICALCITOL HYPERPARATHYROIDISM NHS ENGLAND OTHER ENDOCRINE DRUGS AS PER CINACALCIT AS PER CINACALCIT AS PER CINACALCIT AS PER CINACALCIT √
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 7 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
PARITAPREVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
PASIREOTIDE ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUESNOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY 16003/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PASIREOTIDE CUSHING'S DISEASE NHS ENGLAND SOMATOSTATIN ANALOGUESNHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16052/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
PATISIRAN AMYLOIDOSIS NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PAZOPANIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA215 NICE NICE SACT √
PEG INTERFERON ALFA HEPATITIS B AND C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: B07/P/a; TA75,
TA96, TA106, TA200, TA 300
CG165
NICE NICE NICE AUDIT √
PEGINTERFERON BETA-1A MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS
ROUTINELY COMMISSIONED AS PER
SSC1534: MULTIPLE SCLEROSIS FIRST
LINE DISEASE MODIFYING AGENTS
NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
PRETOMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PROTEIN CAS PER BCSH GUIDELINES FOR
SPECIALISED INDICATIONSNHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
PROTHROMBIN COMPLEXAS PER BCSH GUIDELINES FOR
SPECIALISED INDICATIONSNHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
HAEMOGLOBINURIANOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RAXIBACUMAB INHALED ANTHRAX NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
REFANALINPREVENTION OF DELAYED GRAFT
FUNCTIONNHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
REGORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA488 & TA555 NICE NICE SACT √ √
REPARIXINPREVENTION OF DELAYED GRAFT
FUNCTIONNHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RIGOSERTIB MDS/PANCREATIC CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RIMEPORIDE DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RIOCIGUATPULMONARY ARTERIAL
HYPERTENSION (CTEPH)NHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A11/P/cNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RIOCIGUATPULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16055/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY: E03/P/bNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RITUXIMABSTEROID RESISTANT NEPHROTIC
SYNDROMENHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: E03/P/cNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RITUXIMABPRIMARY SJOGREN'S SYNDROME
(PSS)NHS ENGLAND CYTOKINE MODULATORS
NOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY 16048/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RITUXIMABCHRONIC INFLAMMATORY
DEMYELINATING POLYNEUROPATHYNHS ENGLAND CYTOKINE MODULATORS
NOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY 170026/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RITUXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORSNHS ENGLAND CLINICAL
COMMISSIONING POLICY: E03/P/dNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
RITUXIMAB ACQUIRED HAEMOPHILIA NHS ENGLAND CYTOKINE MODULATORSNHS ENGLAND CLINICAL
COMMISSIONING POLICY: F02/P/aNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RITUXIMAB ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORSTA308
NHS ENGLAND POLICY: A13/P/a
NICE/ NHS ENGLAND
POLICY
NICE/ NHS ENGLAND
POLICYNICE/ NHS ENGLAND POLICY √
RITUXIMABANTI-NMDAR AUTOIMMUNE
ENCEPHALITISNHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:16036/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
RITUXIMABCONNECTIVE TISSUE DISEASE -
INTERSTITIAL LUNG DISEASENHS ENGLAND CYTOKINE MODULATORS
NOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY 170015/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RITUXIMABCYTOPENIA COMPLICATING PRIMARY
IMMUNODEFICIENCYNHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:16044/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 8 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
RITUXIMABCHRONIC GRAFT VERSUS HOST
DISEASENHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:16069/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RITUXIMAB SLE NHS ENGLAND CYTOKINE MODULATORSNHS ENGLAND CLINICAL
COMMISSIONING POLICY: A13/PS/aNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RITUXIMAB MEMBRANOUS NEPHROPATHY NHS ENGLAND CYTOKINE MODULATORSNOT ROUTINELY COMMISSIONED
NHS ENGLAND POLICY 16047/PAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RITUXIMABDERMATOMYOSITIS AND
POLYMYOSITIS (ADULTS)NHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:16036/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RITUXIMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √
RITUXIMABABO-INCOMPATIBLE KIDNEY
TRANSPLANTSNHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √
RITUXIMABPEMPHIGUS VULGARIS AND
PEMPHIGOID DISEASENHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:16035/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RITUXIMAB IMMUNOGLOBIN G4 RELATED DISEASE NHS ENGLAND CYTOKINE MODULATORSNHS ENGLAND CLINICAL
COMMISSIONING POLICY:16057/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
RITUXIMAB MYASTHENIA GRAVIS NHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY STATEMENT
170084P
NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
RITUXIMAB IV CANCER NHS ENGLAND CYTOKINE MODULATORS
TA65, TA137, TA174, TA193, TA226,
TA243
NHS ENGLAND CDF LETTER
TA65, TA137, TA174, TA193,
TA226, TA243
NHS ENGLAND CDF LETTER
TA65, TA137, TA174, TA193,
TA226, TA243
NHS ENGLAND CDF LETTER
SACT √
RITUXIMAB SUBCUTANEOUS
FORMULATIONCANCER NHS ENGLAND CYTOKINE MODULATORS
AS PER CIRCULAR IE ONLY
COMMISSIONED FOR FOLLICULAR
LYMPHOMA MAINTENANCE TREATMENT
AS PER CIRCULAR AS PER CIRCULAR SACT √
RIVIPANSEL SODIUM HEPATIC VENO-OCCLUSIVE DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RIVIPANSEL SODIUM SICKLE CELL DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ROMIPLOSTIM ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 221 NICE NICE NICE AUDIT √ √
ROPEGINTERFERON ALFA-2b HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ROXADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLANDDRUGS USED IN HYPOPLASTIC,
HAEMOLYTIC, AND RENAL ANAEMIASNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RURIOCTOCOG ALFA PEGOL HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RUZASVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RUXOLITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 386 NICE NICE SACT √
SACROSIDASECONGENITAL SUCRASE ISOMALTASE
DEFICIENCYNHS ENGLAND
DRUGS USED IN METABOLIC
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SAPROPTERINADULTS AND CHILDREN WITH
PHENYLKETONURIANHS ENGLAND
DRUGS USED IN METABOLIC
DISORDERS
NOT ROUTINELY COMMISSIONED
(NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 170103P)
AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SAPROPTERIN MATERNAL PHENYLKETONURIA NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: E12/P/aNHS ENGLAND POLICY NHS ENGLAND POLICY HIGHLY SPECIALISED DATABASE √
SATRALIZUMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SEBELIPASE ALFA LYSOSOMAL ACID LIPASE DEFICIENCY NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERS
NOT ROUTINELY COMMISSIONED
NICE HST IN PROGRESSAS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SELEXIPAGPULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 170104PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
SEVELAMER ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
SIPONIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SIROLIMUS (RAPAMUNE)TRANSPLANT IMMUNOSUPPRESSION
ONLYNHS ENGLAND
DRUGS AFFECTING THE IMMUNE
RESPONSE
TA481, TA482
NEW PATIENTS ONLY UNTIL FORMAL
REPATRIATION AGREED
NICE NICEPRODUCT WITH LOWEST
PROCUREMENT COST TO BE USED√* √*
SODIUM OXYBATENARCOLEPSY - PEADIATRIC SERVICES
ONLYNHS ENGLAND HYPNOTICS & ANXIOLYTICS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16065/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
SODIUM PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
SOFOSBUVIR/DACLATASVIR +
RIBAVIRINHEPATITIS C NHS ENGLAND
VIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA 364 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
SOFOSBUVIR/LEDIPASVIR +/-
RIBAVIRINHEPATITIS C NHS ENGLAND
VIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA 363 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
SOFOSBUVIR/PEGINTERFERON+
RIBAVIRINHEPATITIS C NHS ENGLAND
VIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA 330 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
SOFOSBUVIR/VELPATASVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA 430 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
SORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 474 & TA 535 NICE NICE SACT √ √
SUCROFERRIC OXYHDROXIDE ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
SUNITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA169, TA179, TA449 NICE NICE SACT √ (Only TA449) √
TABALUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TAFAMANDIS AMYLOIDOSIS NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TALIGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
TARIBAVIRIN HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TEDUGLUTIDE SHORT BOWEL SYNDROME NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TELAPREVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSTA252 NICE NICE HEPATITIS C MDS √
TELBIVUDINE HEPATITIS B NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUS
NOT ROUTINELY COMMISSIONED
(TA154)AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TEMSIROLIMUS CANCER NHS ENGLAND PROTEIN KINASE INHIBITORSNOT ROUTINELY COMMISSIONED
(TA178)IFR IFR SACT √
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 9 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
TENOFOVIR
HIV IN COMBINATION WITH OTHER
ANTI-RETROVIRAL DRUGS
HEPATITIS B +/- OTHER ANTI-
RETROVIRAL DRUGS
NHS ENGLAND AIDS/HIV ANTIRETROVIRALSTA173 (FOR HEPATITIS B)/AGREED
REGIONAL GUIDELINES FOR HIV
BHIVA GUIDELINES (8)
NICE
BHIVA GUIDELINES (8)
NICEHARS DATASET √
TENOFOVIR ALAFENAMIDE HEPATITIS B NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TENOFOVIR ALAFENAMIDEHIV IN COMBINATION WITH OTHER
ANTI-RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16043/PNHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
TENOFOVIR ALAFENAMIDE +
COBICISTAT + ELVITEGRAVIR +
EMTRICITABINE
HIV IN COMBINATION WITH OTHER
ANTI-RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: 16043/PNHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
TENOFOVIR DISOPROXIL +
COBICISTAT + ELVITEGRAVIR +
EMTRICITABINE
HIV IN COMBINATION WITH OTHER
ANTI-RETROVIRAL DRUGSNHS ENGLAND AIDS/HIV ANTIRETROVIRALS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY:
F03/P/b/AGREED REGIONAL GUIDELINES
NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
TOBRAMYCIN CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: A01/P/b
TA276
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY
NICE
NHS ENGLAND POLICY
NICE AUDIT√* √*
TOCILIZUMAB ADULT ONSET STILLS DISEASE NHS ENGLAND CYTOKINE MODULATORSNHS ENGLAND CLINICAL
COMMISSIONING POLICY 170056PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
TOCILIZUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY: E03/P/d; TA
373
NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
TOCILIZUMAB TAKAYASU ARTERITIS NHS ENGLAND CYTOKINE MODULATORSNHS ENGLAND CLINICAL
COMMISSIONING POLICY 16056/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
TOCILIZUMAB GIANT CELL ARTERITIS NHS ENGLAND CYTOKINE MODULATORS TA 518 NICE NICE NICE AUDIT √ √
TOLVAPTAN HYPONATRAEMIA IN CANCER NHS ENGLANDPOSTERIOR PITUITARY HORMONES
AND ANTAGONISTS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY 16051/PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
TRALOKINUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRENONACOG ALPHA HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TREPROSTINIL DIETHANOLAMINE PULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TREPROSTINIL SODIUMPULMONARY ARTERIAL
HYPERTENSIONNHS ENGLAND
VASODILATOR ANTIHYPERTENSIVE
DRUGS/PULMANORY ARTERIAL
HYPERTENSION
NOT ROUTINELY COMMISSIONED FOR
NEW PATIENTS - NHS ENGLAND
CLINICAL COMMISSIONING POLICY:
A11/P/c
AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRIENTENE WILSONS DISEASE NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERS
NHS ENGLAND CLINICAL
COMMISSIONING POLICY 170094PNHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
TRIHEPTANOIN PYRUVATE CARBOXYLASE DEFICIENCY NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
UPRIFOSBUVIR HEPATITIS C NHS ENGLANDVIRAL HEPATITIS (B&C) &
RESPIRATORY SYNCYTIAL VIRUSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VADADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLANDDRUGS USED IN HYPOPLASTIC,
HAEMOLYTIC, AND RENAL ANAEMIASNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VANDETANIB THYROID CANCER NHS ENGLAND PROTEIN KINASE INHIBITORSNOT ROUTINELY COMMISSIONED
(TA550)IFR IFR SACT √
VATIQUINONE FRIEDREICHS ATAXIA NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VELAGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLANDDRUGS USED IN METABOLIC
DISORDERSNHS ENGLAND SERVICE SPECIFICATION
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLYHIGHLY SPECIALISED DATABASE √
VELCALCETIDE HYPERPARATHYROIDISM NHS ENGLANDDRUGS AFFECTING BONE
METABOLISMNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VELMANASE ALFA ALPHA MANNOSIDASE DEFICIENCY NHS ENGLANDDRUGS USED TO TREAT ALPHA
MANNOSIDOSISNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VEMURAFENIB MELANOMA NHS ENGLAND PROTEIN KINASE INHIBITORS TA269 NICE NICE NICE AUDIT √
VESTRONIDASE ALFA MUCOPOLYSACCHARIDOSIS VII NHS ENGLANDLYSOSOMAL STORAGE DISORDER
DRUGSNOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VOLANESORSENFAMILIAL CHYLOMICRONEMIA
SYNDROMENHS ENGLAND LIPID-REGULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VONICOG ALFA VON WILLEBRAND DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VON WILLEBRAND FACTOR,
RECOMBINANTVON WILLEBRAND DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 10 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
VORICONAZOLECHRONIC PULMONARY
ASPERGILLOSISNHS ENGLAND ANTIFUNGALS HIGHLY SPECIALISED CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLY
HIGHLY SPECIALISED
CRITERIA ONLY√
VOXELOTOR SICKLE CELL DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VX-210 SPINAL CORD INJURY NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DARATUMUMAB CANCER CDF CANCER EXCLUSION CDF (TA 510) CDF CDF SACT √
DINUTUXIMAB CANCER NHS ENGLAND CANCER EXCLUSION TA 538 NICE NICE SACT √ √
DOCETAXEL CANCER NHS ENGLAND CANCER EXCLUSION
NHS ENGLAND CLINICAL
COMMISSIONING POLICY STATEMENT
B15/PS/a
NHS ENGLAND POLICY NHS ENGLAND POLICY SACT √
ERIBULIN CANCERNHS ENGLAND/
CDFCANCER EXCLUSION
NICE TA 423
CDF POLICY
NICE
CDF
NICE
CDF SACT √ √
FACTOR X (COAGADEX) HEREDITARY FACTOR X DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GEMCITABINE (WITH
CAPECITABINE)CANCER NHS ENGLAND CANCER EXCLUSION NHS ENGLAND POLICY 170101P NHS ENGLAND POLICY NHS ENGLAND POLICY SACT √ √
GEMTUZUMAB OZOGAMICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 545 NICE NICE SACT √ √
IBRUTINIB CANCER NHS ENGLAND/CDF PROTEIN KINASE INHIBITORSTA429, TA502
CDF (TA491)
NICE
CDF
NICE
CDF SACT √ √
IDELALISIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 359 NICE NICE SACT √
INOTUZUMAB OZOGAMICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 541 NICE NICE SACT √ √
IPILIMUMAB CANCER NHS ENGLAND CANCER EXCLUSION TA268, TA319, 400 NICE NICE SACT √
LENVATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA498, TA 535 & TA 551 NICE NICE SACT √ √
LIPOSOMAL CYTARABINE-
DAUNORUBICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 522 NICE NICE SACT √ √
LUTETIUM (177Lu)
OXODOTREOTIDE CANCER NHS ENGLAND CANCER EXCLUSION TA 539 NICE NICE SACT √ √
MESENCHYMAL STEM CELLS (E.G.
PROCHYMAL®)
ACUTE GVHD AND OTHER INDICATIONS
(BCSH)NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MIDOSTAURIN CANCER NHS ENGLAND CANCER EXCLUSION TA 523 NICE NICE SACT √ √
MYCOPHENOLATE MOFETILTRANSPLANT IMMUNOSUPPRESSION
ONLYNHS ENGLAND
TA481, TA482
NEW PATIENTS ONLY UNTIL FORMAL
REPATRIATION AGREED
NICE NICEPRODUCT WITH LOWEST
PROCUREMENT COST TO BE USED√* √*
MYCOPHENOLIC ACIDTRANSPLANT IMMUNOSUPPRESSION
ONLYNHS ENGLAND
TA481, TA482
NEW PATIENTS ONLY UNTIL FORMAL
REPATRIATION AGREED
NICE NICEPRODUCT WITH LOWEST
PROCUREMENT COST TO BE USED√* √*
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 11 04/04/2019
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIAMONITORING/AUDIT
REQUIREMENTS
PRIOR
APPROVAL
PROFORMA
REQUIRED
SPECIALIST
CENTRE ONLY
(includng
outreach when
delivered as part
of a provider
network)
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
AND
SECONDARY
CARE VIA
NETWORK
MODEL
SUITABLE FOR
SHARED CARE
WITH PRIMARY
CARE (IF
SUPPORTED BY
LOCAL
PRESCRIBING
COMMITTEE)
NELARABINE CANCER CDF CANCER EXCLUSION CDF POLICY CDF CDF SACT √
NIRAPARIB CANCER CDF CANCER EXCLUSION CDF (TA 528) CDF CDF SACT √ √
NIVOLUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSIONTA 384, 400, 417, 462, 530
CDF (TA 483, TA 484, TA 490, TA 558,)
NICE
CDF
NICE
CDF SACT √ √
OBINUTUZUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSIONTA343 & 513
CDF (TA472)
NICE
CDF
NICE
CDFSACT √ √
OLAPARIB CANCER NHS ENGLAND CANCER EXCLUSION TA 381 NICE NICE SACT √
OLARATUMAB CANCER CDF CANCER EXCLUSION CDF (TA 465) CDF CDF SACT √ √
OSIMERTINIB CANCER CDF CANCER EXCLUSION CDF (TA 416) CDF CDF SACT √ √
PALBOCICLIB CANCER NHS ENGLAND CANCER EXCLUSION TA 495 NICE NICE SACT √ √
PANITUMUMAB CANCER NHS ENGLAND CANCER EXCLUSION TA439 NICE NICE SACT √ √
PANOBINOSTAT CANCER NHS ENGLAND CANCER EXCLUSION TA 380 NICE NICE SACT √
PEGASPARGASE CANCER NHS ENGLAND CANCER EXCLUSION TA 408 NICE NICE SACT √
PEGYLATED LIPOSOMAL
DOXORUBICINCANCER
NHS ENGLAND/
CDFCANCER EXCLUSION
TA91
CDF POLICY
NICE
CDF
NICE
CDFSACT √
PEMETREXED CANCER NHS ENGLAND CANCER EXCLUSIONTA135, TA181, TA190, TA 402
NICE NICE SACT √
PEPTIDE RECEPTOR
RADIONUCLEOTIDE THERAPYCANCER CDF NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PERTUZUMAB CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 424, TA 509 and TA 569 NICE NICE SACT √ √
PIXANTRONE CANCER NHS ENGLAND CANCER EXCLUSION TA306 NICE NICE SACT √
PROTEIN KINASE INHIBITORSENDOCRINOLOGY; NON-MALIGNANT
CONDITIONSNHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RADIUM-223 DICHLORIDE CANCERNHS ENGLAND/
CDFCANCER EXCLUSION NICE TA 376, TA 412
NICE
CDF
NICE
CDFSACT √
RAMUCIRUMAB CANCER NHS ENGLAND CANCER EXCLUSIONNOT ROUTINELY COMMISSIONED -
TA 378AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
RIBOCICLIB CANCER NHS ENGLAND CANCER EXCLUSION TA 496 NICE NICE SACT √ √
STRIMVELIS
ADENOSINE DEAMINASE DEFICIENCY-
SEVERE COMBINED
IMMUNODEFICIENCY
NHS ENGLAND ATMP HST7 NICE NICE NICE AUDIT √
TACROLIMUSTRANSPLANT IMMUNOSUPPRESSION
ONLYNHS ENGLAND
TA481, TA482
NEW PATIENTS ONLY UNTIL FORMAL
REPATRIATION AGREED
NICE NICEPRODUCT WITH LOWEST
PROCUREMENT COST TO BE USED√* √*
TALIMOGENE LAHERPAREPVEC CANCER NHS ENGLAND CANCER EXCLUSION TA 410 NICE NICE SACT √ √
TEMOZOLOMIDEENDOCRINOLOGY; NON-MALIGNANT
CONDITIONSNHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TISAGENLECLEUCEL CANCER CDF ATMP CDF (TA 554, TA 567)NICE
CDF
NICE
CDF SACT √ √
TIVOZANIB CANCER NHS ENGLAND CANCER EXCLUSION TA 512 NICE NICE SACT √ √
TRABECTEDIN CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA185 NICE NICE SACT √
TRAMETINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 396 & TA 544 NICE NICE SACT √ √
TRASTUZUMAB CANCER NHSE ENGLAND CANCER EXCLUSION TA 34, 107, 208 NICE NICE SACT √
TRASTUZUMAB EMTANSINE CANCER NHS ENGLAND CANCER EXCLUSION TA 458 NICE NICE SACT √ √
TRIFLURIDINE–TIPIRACIL CANCER NHS ENGLAND CANCER EXCLUSION TA 405 NICE NICE SACT √ √
VENETOCLAX CANCER NHS ENGLAND/CDF CANCER EXCLUSIONTA 487
CDF
NICE
CDF
NICE
CDFSACT √ √
* DRUG IS BEING REPATRIATED FROM PRIMARY TO SECONDARY CARE THEREFORE SUPPLY ROUTE MAY VARY AT PRESENT
NEW LINES ADDED TO V13 LIST
CHANGES TO V13 18/19 LIST
ADDITIONAL NOTES:1. WHERE THE FUNDED INDICATION IS FOR PAEDIATRIC USE THE CCG WILL BECOME THE RESPONSIBLE COMMISSIONER WHEN THE PATIENT IS TRANSFERRED TO THE ADULT SERVICE
2. CCGS ARE THE RESPONSIBLE COMMISSIONER FOR RITUXIMAB IN ADULT NON CANCEROUS HAEMOTOLOGICAL CONDITIONS (EG ITP) AND NON SPECIALIST AUTO-INFLAMMATORY CONDITIONS (EG RA)
6. NHS ENGLAND IS THE RESPONSIBLE COMMISSIONER WHEN SOMATROPIN ANALOGUES (GROWTH HORMONE) ARE PRESCRIBED IN SPECIALIST CENTRES FOR INDICATIONS FALLING OUTSIDE NICE GUIDANCE
** ROUTINELY COMMISSIONED IN COMBINATION WHEN DUAL THERAPY REQUIRED
*** ONLY WHEN PRESCRIBED IN AN ADULT SPECIALIST CENTRE
**** ONLY WHERE IT IS A RECOGNISED MS CENTRE WITH SPECIALIST NURSE SUPPORT
8.DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN AS PER THE NHS ENGLAND MEDICINES FOR
CHILDREN POLICY FOUND AT https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/ AND A BLUETEQ FORM IS AVAILABLE. THIS INCLUDES FOR DRUGS NORMALLY COMMISISONED BY CCG'S IN ADULTS EG ADALIMUMAB, ETANERCEPT, INFLIXIMAB ETC PLEASE NOTE THAT MEDICINES FUNDED UNDER THE
NHS ENGLAND MEDICINES FOR CHILDREN POLICY MAY HAVE ADDITIONAL CRITERIA WITH RESPECT TO ACCESS
7. NHS ENGLAND COMMISSIONS ARVS AS PER PUBLISHED POLICIES, FOR THE TREATMENT OF PEOPLE WITH DIAGNOSED HIV INFECTION AND FOR THOSE THOUGHT TO BE HIV POSITIVE (POST EXPOSURE PROPHYLAXIS). NHS ENGLAND DOES NOT ROUTINELY COMMISSION PRE-EXPOSURE PROPHYLAXIS AND THIS IS ONLY AVAILABLE TO
THOSE ENROLLED IN CLINICAL STUDIES OR OTHER NHS ENGLAND AGREED SCHEMES
3. ELTROMBOPAG AND ROMIPLOSTIM ARE THE RESPONSIBILTY OF CCGS REGARDLESS OF THE CAUSE OF THE THROMBOCYTOPENIA IN ADULTS (PAEDIATRICS ARE NHS
ENGLAND RESPONSIBILITY)
5. USE IN VASCULAR DISEASE IS COMMISSIONED BY NHS ENGLAND WITHIN SPECIALIST CENTRES - CCG's ARE RESPONSIBLE FOR ALL OTHER INDICATIONS
4. IT IS A MANDATED REQUIREMENT THAT ALL USE OF CHEMOTHERAPY IS RECORDED IN THE SACT DATABASE INCLUDING THOSE TREATMENTS FUNDED THROUGH THE CDF
NHS England drugs-list v14final.xlsx NHSE Commissioned PbRE Drugv14 12 04/04/2019